BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 21, 2007
View Archived Issues
Potential new therapies for immunological disorders reported in the patent literature
Read More
Recent patents cover HDAC inhibitors primarily for cancer
Read More
Curcumin derivative boosts immune system to clear Abeta deposits in Alzheimer's
Read More
Antiinflammatory mechanism for quinacrine identified
Read More
Altus begins phase I trial of ALTU-237 for hyperoxalurias and kidney stone prevention
Read More
Bone primary cilia: a potential target to prevent bone loss
Read More
MPA approves phase I/II study of ChronVac-C hepatitis vaccine
Read More
Romark begins phase II Alinia trial for chronic hepatitis C
Read More
Icagen partners with Pfizer in ion channel-based therapies for pain and related disorders
Read More
Oramed successfully completes oral insulin phase Ia trial
Read More
Myriad begins third phase II trial of Azixa for lung cancer spread to the brain
Read More
Positive results for Cephalon's phase III trial of Fentora for noncancer breakthrough pain
Read More
HealthLinx initiates phase II biomarker trial of Ovplex test for ovarian cancer
Read More
UCB submits MAA for Vimpat for neuropathic pain to EMEA
Read More
FDA grants fast track designation to Adventrx's CoFactor
Read More
EMEA reviews new indication for Bioenvision's Evoltra
Read More
Auxilium cleared to resume clinical trials for Xiaflex
Read More
EMEA accepts Jerini's marketing application for icatibant in HAE
Read More
Boston-based investigators focus on the identification of necroptosis inhibitors
Read More
Potent, orally active lead LTB4 hydrolase inhibitor selected at J&J
Read More
FDA approves Anesiva's innovative powder analgesic, Zingo, for use in children
Read More
XOMA-052 to enter the clinic for the treatment of type 2 diabetes
Read More
M2-selective development candidate for OAB presented by Theravance
Read More
Wyeth continues to search for potent, orally active LXR agonists with good selectivity
Read More